From left: Kalev Kallemets, chief executive officer of Fermi Energia, and James Lauritsen, managing director of Laurentis Energy Partners. (Photo: Fermi Energia)

Laurentis Energy Partners will work with Fermi Energia to support the development of small modular reactors in Estonia, the companies announced yesterday at the 2022 Canadian Nuclear Association Conference being held in Ottawa, Ontario.

A subsidiary of Ontario Power Generation (OPG), Laurentis bills itself as a provider of SMR services throughout the development life cycle, from feasibility and planning through construction, commissioning, and operations. Fermi Energia is an Estonian energy company focused on SMR development and deployment.

What they’re saying: “Building on our owner’s engineer and nuclear management experience, Laurentis is pleased to work with Fermi Energia to provide an opportunity for Estonia to confidently introduce SMRs into their energy mix,” stated Jason Van Wart, vice president of Laurentis.

The Canadian Nuclear Safety Commission (CNSC) has amended Ontario Power Generation’s (OPG) operating license for its Darlington nuclear power station near Clarington, Ontario, allowing the company to produce the medical radioisotope molybdenum-99 using Darlington’s Unit 2 CANDU reactor. OPG subsidiary Laurentis Energy Partners, in conjunction with BWXT Medical, is leading the program to produce Mo-99 at Darlington.

Laurentis Energy Partners, a subsidiary of Ontario Power Generation (OPG), has launched a new program to produce helium-3. The He-3 will be obtained from tritium stored at OPG’s Darlington nuclear power plant, a four-unit CANDU station located about 100 kilometers east of Toronto.

Darlington houses one of the world’s largest reserves of tritium, which is a by-product of the heavy water used in CANDU reactors.

Darlington nuclear generating station. Photo: OPG

Ontario Power Generation, its subsidiary Laurentis Energy Partners, and BWXT ITG Canada and its affiliates announced on September 24 that the companies are making “significant progress” toward the production of molybdenum-99 at OPG’s Darlington nuclear power plant. Darlington will become the first commercial operating nuclear reactor to produce the medical radioisotope.

A precursor to technetium-99m, Mo-99 is used in more than 40 million procedures a year to detect cancers and diagnose various medical conditions.